文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

类风湿关节炎相关间质性肺病治疗结局:免疫抑制对肺功能轨迹影响的真实世界多中心研究

Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.
PubMed 文献 · Chest · 2022-12-05
一句话结论在5家ILD中心的回顾性队列中,免疫抑制治疗与FVC%预计值和Dlco%预计值12个月轨迹改善相关,UIP模式与药物选择未显著影响轨迹。

本研究为多中心回顾性队列,纳入212例开始接受霉酚酸酯、硫唑嘌呤或利妥昔单抗治疗的类风湿关节炎相关间质性肺病患者,采用线性样条混合效应模型比较治疗前后肺功能轨迹。三种药物合并分析显示,治疗12个月后FVC%预计值较未治疗的潜在12个月反应改善+3.90%(P≤.001,95%CI 1.95-5.84),Dlco%预计值改善+4.53%(P≤.001,95%CI 2.12-6.94)。UIP型与非UIP型之间、不同免疫抑制剂之间,肺功能轨迹均无显著差异。作者认为免疫抑制与FVC和Dlco轨迹改善相关,但需前瞻性随机试验验证。

要点

  • 212例RA-ILD患者中,硫唑嘌呤92例(43.4%)、霉酚酸酯77例(36.3%)、利妥昔单抗43例(20.3%)。
  • 三种药物合并分析:治疗12个月FVC%预计值较未治疗潜在反应改善+3.90%(P≤.001,95%CI 1.95-5.84)。
  • Dlco%预计值在12个月时改善+4.53%(P≤.001,95%CI 2.12-6.94)。
  • UIP型与非UIP型之间、不同免疫抑制剂之间,肺功能轨迹无显著差异。
  • 作者认为免疫抑制与FVC和Dlco轨迹改善相关,需前瞻性随机试验验证。

适用人群与场景

  • 从5家ILD中心回顾性识别的类风湿关节炎患者,因ILD开始接受霉酚酸酯、硫唑嘌呤或利妥昔单抗治疗。

处置流程与药物剂量

  • 免疫抑制方案包括硫唑嘌呤(92例,43.4%)、霉酚酸酯(77例,36.3%)、利妥昔单抗(43例,20.3%);原文未给出具体剂量、给药途径与频次。

研究设计与关键结果

  • 多中心回顾性队列,纳入212例RA-ILD患者,来自5家ILD中心;92例(43.4%)用硫唑嘌呤,77例(36.3%)用霉酚酸酯,43例(20.3%)用利妥昔单抗。
  • 三种药物合并分析:治疗12个月后FVC%预计值较未治疗的潜在12个月反应改善+3.90%(P≤.001,95%CI 1.95-5.84)。
  • 治疗12个月后Dlco%预计值改善+4.53%(P≤.001,95%CI 2.12-6.94)。
  • UIP型ILD与药物选择均未显著影响免疫抑制下的肺功能轨迹。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为免疫抑制与FVC和Dlco轨迹改善相关,需前瞻性随机试验验证这些发现。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) is common in patients with RA and leads to significant morbidity and mortality. No randomized, placebo-controlled data are available that support the role of immunosuppression to treat RA-associated ILD, despite being widely used in clinical practice.

RESEARCH QUESTION: How does immunosuppression impact pulmonary function trajectory in a multisite retrospective cohort of patients with RA-associated ILD?

STUDY DESIGN AND METHODS: Patients with RA who started treatment for ILD with mycophenolate, azathioprine, or rituximab were identified retrospectively from five ILD centers. Change in lung function before and after treatment was analyzed using a linear spline mixed-effect model with random intercept. Prespecified secondary analyses examined the impact of radiologic pattern of ILD (ie, usual interstitial pneumonia [UIP] vs non-UIP) on treatment trajectory.

RESULTS: Two hundred twelve patients were included in the analysis: 92 patients (43.4%) were treated with azathioprine, 77 patients (36.3%) were treated with mycophenolate mofetil, and 43 patients (20.3%) were treated with rituximab. In the combined analysis of all three agents, an improvement in FVC % predicted was found after 12 months of treatment compared with the potential 12-month response without treatment (+3.90%; P ≤ .001; 95% CI, 1.95-5.84). Diffusing capacity of the lungs for carbon monoxide (Dlco) % predicted also improved at 12 months (+4.53%; P ≤ .001; 95% CI, 2.12-6.94). Neither the UIP pattern of ILD nor choice of immunosuppressive agent significantly impacted the pulmonary function trajectory on immunosuppression.

INTERPRETATION: Immunosuppression was associated with an improved trajectory in FVC and Dlco compared with the pretreatment pulmonary function trajectory. Prospective, randomized trials are required to validate these findings.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Matson SM, Baqir M, Moua T, et al. Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory. Chest. 2022. PMID: 36470416. doi:10.1016/j.chest.2022.11.035

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。